{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:19:37Z","timestamp":1791199177417,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background. \u2003Dolutegravir has shown in vitro activity against human immunodeficiency virus type 2 (HIV-2). We report safety and efficacy data of regimens containing dolutegravir (50 mg twice daily) in antiretroviral-experienced, HIV-2\u2013infected patients.<\/jats:p>\n                  <jats:p>Methods. \u2003HIV-2\u2013infected patients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP). Plasma HIV-2 RNA (pVL) was assessed at time of dolutegravir initiation (baseline), month 3, and month 6. Antiretroviral trough plasma concentrations (C12h) were determined using liquid chromatography coupled with tandem mass spectrometry.<\/jats:p>\n                  <jats:p>Results. \u2003Thirteen HIV-2\u2013infected-patients, with a median duration of 15 years\u2019 infection and given 16 previous antiretroviral regimens, were included in NPP. Median follow-up was 9 months (min\u2013max, 3\u201315 months). Median baseline pVL and CD4 cell count were 9544 copies\/mL (inter quartile range [IQR], 3096\u201323 120 copies\/mL) and 100 cells\/\u00b5L (IQR, 77\u2013171 cells\/\u00b5L), respectively. Available integrase genotypic resistance patterns were Y143C\/G\/H\/R (n = 5), Q148R\/K (n = 2), and N155H (n = 4). Optimized background antiretroviral regimens conferring a genotypic sensitivity score \u22642 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunavir\/ritonavir (n = 12), saquinavir\/ritonavir (n = 2), and maraviroc (n = 3). At months 3 and 6, pVL was undetectable in 6 of 13 and 4 of 12 patients, respectively, and median CD4 count was 161 (101\u2013188) cells\/\u00b5L and 167 (135\u20131353) cells\/\u00b5L, respectively. Median dolutegravir C12h was 4086 (1756\u20135717 ng\/mL) ng\/mL in 9 patients. No serious events were notified except 1 death from progressive multifocal leukoencephalopathy at month 4.<\/jats:p>\n                  <jats:p>Conclusions. \u2003Optimized dolutegravir-containing antiretroviral regimens supported by good plasma exposure provide a substantial initial efficacy rate for salvage therapy in heavily antiretroviral-experienced HIV-2\u2013infected patients with virus harboring resistance to first-generation integrase inhibitors. Larger numbers of patients and longer follow-up are needed to confirm these findings.<\/jats:p>","DOI":"10.1093\/cid\/civ124","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T20:16:47Z","timestamp":1424204207000},"page":"1521-1527","source":"Crossref","is-referenced-by-count":26,"title":["Dolutegravir in HIV-2\u2013Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program"],"prefix":"10.1093","volume":"60","author":[{"given":"Diane","family":"Descamps","sequence":"first","affiliation":[{"name":"Universit\u00e9 1"},{"name":"Paris Diderot, Sorbonne Paris Cit\u00e9 1"},{"name":"INSERM 2 ,"},{"name":"IAME, UMR 1137 2 ,"},{"name":"Laboratoire de Virologie 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 1"},{"name":"Paris Diderot, Sorbonne Paris Cit\u00e9 1"},{"name":"INSERM 2 ,"},{"name":"IAME, UMR 1137 2 ,"},{"name":"Laboratoire de Pharmaco-Toxicologie 4 ,"},{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard 4 ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Visseaux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 1"},{"name":"Paris Diderot, Sorbonne Paris Cit\u00e9 1"},{"name":"INSERM 2 ,"},{"name":"IAME, UMR 1137 2 ,"},{"name":"Laboratoire de Virologie 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re 5"},{"name":"Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, UPMC, INSERM UMR-S1136 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[{"name":"Universit\u00e9 1"},{"name":"Paris Diderot, Sorbonne Paris Cit\u00e9 1"},{"name":"INSERM 2 ,"},{"name":"IAME, UMR 1137 2 ,"},{"name":"Laboratoire de Virologie 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Campa","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Saint-Antoine 7 , Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 1"},{"name":"Paris Diderot, Sorbonne Paris Cit\u00e9 1"},{"name":"INSERM 2 ,"},{"name":"IAME, UMR 1137 2 ,"},{"name":"Laboratoire de Virologie 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aude","family":"Khuong-Josses","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, H\u00f4pital Delafontaine 8 , Saint-Denis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Necker, Centre d'Infectiologie Necker-Pasteur, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9 9"},{"name":"IHU Imagine 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Karmochkine","sequence":"additional","affiliation":[{"name":"Service d'Immunologie Clinique, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou 11 , Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuna","family":"Lukiana","sequence":"additional","affiliation":[{"name":"ViiV Healthcare 12 , Marly le Roi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Matheron","sequence":"additional","affiliation":[{"name":"Universit\u00e9 1"},{"name":"Paris Diderot, Sorbonne Paris Cit\u00e9 1"},{"name":"INSERM 2 ,"},{"name":"IAME, UMR 1137 2 ,"},{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard 13 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"key":"2024111411393158700_CIV124C1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/aid.2008.0015","article-title":"HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal","volume":"24","author":"Gottlieb","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411393158700_CIV124C2","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1097\/QAD.0b013e3282f15637","article-title":"Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003\u20132006","volume":"21","author":"Barin","year":"2007","journal-title":"AIDS"},{"key":"2024111411393158700_CIV124C3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/aid.2008.0259","article-title":"Molecular epidemiology of HIV type 2 infections in South India","volume":"25","author":"Gurjar","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411393158700_CIV124C4","first-page":"934","article-title":"HIV-1 and HIV-2 AIDS in African patients living in Paris","volume":"11","author":"Matheron","year":"1997","journal-title":"AIDS"},{"key":"2024111411393158700_CIV124C5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1128\/JCM.44.4.1543-1546.2006","article-title":"Molecular investigation of human immunodeficiency virus type 2 subtype a cases in South Korea","volume":"44","author":"Nam","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2024111411393158700_CIV124C6","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1086\/597504","article-title":"20 years of HIV-2 infection in Portugal: trends and changes in epidemiology","volume":"48","author":"Valadas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024111411393158700_CIV124C7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2024111411393158700_CIV124C8","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"2024111411393158700_CIV124C9","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"2024111411393158700_CIV124C10","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1021\/bi800791q","article-title":"Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants","volume":"47","author":"Marinello","year":"2008","journal-title":"Biochemistry"},{"key":"2024111411393158700_CIV124C11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.01534-07","article-title":"Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137)","volume":"82","author":"Shimura","year":"2008","journal-title":"J Virol"},{"key":"2024111411393158700_CIV124C12","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"2024111411393158700_CIV124C13","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/JVI.02541-10","article-title":"Differential sensitivities of retroviruses to integrase strand transfer inhibitors","volume":"85","author":"Koh","year":"2011","journal-title":"J Virol"},{"key":"2024111411393158700_CIV124C14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2024111411393158700_CIV124C15","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1097\/QAD.0b013e32834d8e52","article-title":"Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance","volume":"25","author":"Smith","year":"2011","journal-title":"AIDS"},{"key":"2024111411393158700_CIV124C16","doi-asserted-by":"crossref","first-page":"e45372","DOI":"10.1371\/journal.pone.0045372","article-title":"Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS One"},{"key":"2024111411393158700_CIV124C17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2024111411393158700_CIV124C18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2024111411393158700_CIV124C19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2024111411393158700_CIV124C20","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/JCM.00724-14","article-title":"New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load","volume":"52","author":"Avettand-Fenoel","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2024111411393158700_CIV124C21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000000244","article-title":"Genotypic resistance profiles of HIV-2-treated patients in West Africa","volume":"28","author":"Charpentier","year":"2014","journal-title":"AIDS"},{"key":"2024111411393158700_CIV124C22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/infdis\/jir698","article-title":"Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool","volume":"205","author":"Visseaux","year":"2012","journal-title":"J Infect Dis"},{"key":"2024111411393158700_CIV124C23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1089\/0889222041217392","article-title":"Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification","volume":"20","author":"Damond","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411393158700_CIV124C24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jmv.20174","article-title":"High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen","volume":"74","author":"Descamps","year":"2004","journal-title":"J Med Virol"},{"key":"2024111411393158700_CIV124C25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2024111411393158700_CIV124C26","article-title":"Rapport 2013 sur la prise en charge m\u00e9dicale des personnes vivant avec le VIH.: sous la direction du Professeur Philippe Morlat","year":"2013"},{"key":"2024111411393158700_CIV124C27","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2024111411393158700_CIV124C28","article-title":"Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)\u2013naive subjects [abstract A-1573]","author":"Song"},{"key":"2024111411393158700_CIV124C29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"2024111411393158700_CIV124C30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"2024111411393158700_CIV124C31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":"High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024111411393158700_CIV124C32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcv.2008.07.001","article-title":"Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients","volume":"43","author":"Charpentier","year":"2008","journal-title":"J Clin Virol"},{"key":"2024111411393158700_CIV124C33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00002030-200404300-00020","article-title":"Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations","volume":"18","author":"Mathiesen","year":"2004","journal-title":"AIDS"},{"key":"2024111411393158700_CIV124C34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcv.2009.11.008","article-title":"Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure","volume":"47","author":"Stegmann","year":"2010","journal-title":"J Clin Virol"},{"key":"2024111411393158700_CIV124C35","article-title":"Association de Foscarnet et Dolutegravir dans le traitement des infections VIH avanc\u00e9es: une s\u00e9rie de 5 cas [abstract 20]","author":"Delory","year":"2014"},{"key":"2024111411393158700_CIV124C36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411393158700_CIV124C37","article-title":"Dolutegravir treatment of HIV subjects with raltegravir resistance: integrase resistance evolution in cohort II of the VIKING study [abstract 5]","author":"Vavro","year":"2012"},{"key":"2024111411393158700_CIV124C38","article-title":"Raltegravir-associated mutations in HIV-2 confer cross-resistance to dolutegravir in vitro [abstract 574]","author":"Smith","year":"2014"},{"key":"2024111411393158700_CIV124C39","article-title":"Impact of raltegravir\/elvitegravir selected mutations on dolutegravir cross-resistance [abstract 595]","author":"Huang","year":"2014"},{"issue":"Suppl 1","key":"2024111411393158700_CIV124C40","first-page":"A151","article-title":"Characterization of dolutegravir cross resistance among HIV-1 containing raltegravir\/elvitegravir selected resistance mutations","volume":"19","author":"Huang","year":"2014","journal-title":"Antivir Ther"},{"key":"2024111411393158700_CIV124C41","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411393158700_CIV124C42","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"2024111411393158700_CIV124C43","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults","volume":"25","author":"Min","year":"2011","journal-title":"AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/10\/1521\/969847\/civ124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/10\/1521\/969847\/civ124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:46:43Z","timestamp":1731566803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/60\/10\/1521\/339047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,17]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,2,17]]},"published-print":{"date-parts":[[2015,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ124","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725357578.793506644","asserted-by":"object"}]},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5,15]]},"published":{"date-parts":[[2015,2,17]]}}}